M&T Bank Corp Vertex Pharmaceuticals Inc Transaction History

M&T Bank Corp

$29.1 Billion
Q2 2024

A detailed history of M&T Bank Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, M&T Bank Corp holds 19,941 shares of VRTX stock, worth $10 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

19,941

Previous 22,016 9.42%

Holding current value

$10 Million

Previous $9.2 Million 1.56%

% of portfolio

0.03%

Previous 0.03%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$392.81 - $485.53 $815,080 - $1.01 Million	-2,075 Reduced 9.42%	19,941 $9.35 Million
Q1 2024 May 07, 2024	SELL	$407.69 - $446.08 $10.2 Million - $11.1 Million	-24,909 Reduced 53.08%	22,016 $9.2 Million
Q4 2023 Feb 06, 2024	SELL	$343.0 - $410.68 $1.65 Million - $1.98 Million	-4,824 Reduced 9.32%	46,925 $19.1 Million
Q3 2023 Nov 02, 2023	SELL	$338.18 - $362.46 $828,879 - $888,389	-2,451 Reduced 4.52%	51,749 $18 Million
Q2 2023 Aug 09, 2023	BUY	$314.42 - $351.91 $475,088 - $531,736	1,511 Added 2.87%	54,200 $19.1 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $10.1 Million - $11.5 Million	35,703 Added 210.19%	52,689 $16.6 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $532,085 - $598,595	1,862 Added 11.8%	17,647 $5.1 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $188,887 - $212,498	-661 Reduced 3.75%	16,986 $4.91 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $493,441 - $550,565	1,802 Added 12.89%	15,785 $4.15 Million
Q2 2022 Aug 05, 2022	BUY	$234.96 - $292.55 $690,547 - $859,804	2,939 Added 26.61%	13,983 $3.71 Million
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $420,919 - $496,103	1,901 Added 20.79%	11,044 $2.88 Million
Q4 2021 Feb 07, 2022	BUY	$177.01 - $223.45 $11,505 - $14,524	65 Added 0.72%	9,143 $2.01 Million
Q3 2021 Oct 28, 2021	SELL	$181.39 - $202.99 $2.07 Million - $2.32 Million	-11,405 Reduced 55.68%	9,078 $1.65 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $124,680 - $147,031	-665 Reduced 3.14%	20,483 $4.13 Million
Q1 2021 May 06, 2021	SELL	$207.02 - $241.31 $1.01 Million - $1.18 Million	-4,884 Reduced 18.76%	21,148 $4.55 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $704,455 - $939,534	-3,403 Reduced 11.56%	26,032 $6.15 Million
Q3 2020 Nov 06, 2020	BUY	$255.65 - $303.1 $416,709 - $494,053	1,630 Added 5.86%	29,435 $8.01 Million
Q2 2020 Jul 29, 2020	BUY	$225.48 - $295.8 $754,681 - $990,042	3,347 Added 13.68%	27,805 $8.07 Million
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $234,729 - $291,176	1,175 Added 5.05%	24,458 $5.82 Million
Q4 2019 Feb 07, 2020	BUY	$166.71 - $223.91 $416,775 - $559,775	2,500 Added 12.03%	23,283 $5.1 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $816,189 - $918,611	-4,910 Reduced 19.11%	20,783 $3.52 Million
Q2 2019 Aug 12, 2019	BUY	$164.61 - $190.37 $130,371 - $150,773	792 Added 3.18%	25,693 $4.71 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $69,912 - $83,136	-427 Reduced 1.69%	24,901 $4.58 Million
Q4 2018 Feb 01, 2019	BUY	$151.91 - $192.21 $549,762 - $695,607	3,619 Added 16.67%	25,328 $4.2 Million
Q3 2018 Nov 09, 2018	BUY	$167.73 - $192.74 $142,570 - $163,829	850 Added 4.07%	21,709 $4.18 Million
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $86,849 - $101,296	596 Added 2.94%	20,859 $3.54 Million
Q1 2018 May 04, 2018	SELL	$151.6 - $177.13 $134,317 - $156,937	-886 Reduced 4.19%	20,263 $3.3 Million
Q4 2017 Feb 06, 2018	BUY	$137.28 - $155.55 $225,001 - $254,946	1,639 Added 8.4%	21,149 $3.17 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $555,191 - $608,075	3,748 Added 23.78%	19,510 $2.97 Million
Q2 2017 Aug 11, 2017	BUY	N/A	15,762	15,762 $2.03 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account